We are live on ! Find out more
CP

Caligan Partners Portfolio holdings

AUM $1.5B
1-Year Est. Return 518.95%
This Fund
S&P 500
This Quarter Est. Return
+5.87%
1 Year Est. Return
+518.95%
3 Year Est. Return
+1,728.44%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$178M
AUM Growth
+$34.4M
Cap. Flow
+$34.1M
Cap. Flow %
19.18%
Top 10 Hldgs %
98.47%
Holding
13
New
2
Increased
4
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$18M
2
EOLS icon
Evolus
EOLS
+$2.04M
3
EXEL icon
Exelixis
EXEL
+$1.17M
4
ANIK icon
Anika Therapeutics
ANIK
+$134K
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$12.4K

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$3.02M
2
EYPT icon
EyePoint Inc
EYPT
+$763K
3
LAB icon
Standard BioTools
LAB
+$215K

Sector Composition

Rank Sector Weight
1 Healthcare 92.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
1
Liquidia Corp
LQDA
$7.72B
$72.6M 40.81%
9,243,627
– –
ANIK icon
2
Anika Therapeutics
ANIK
$202M
$18.7M 10.52%
720,291
+5,000
+0.7% +$134K
EXEL icon
3
Exelixis
EXEL
$14.2B
$17.4M 9.79%
910,730
+60,730
+7% +$1.17M
LAB icon
4
Standard BioTools
LAB
$311M
$16.3M 9.19%
8,467,920
-108,879
-1% -$215K
ICPT
5
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$14.3M 8.05%
+1,293,510
New +$18M
ICPT
6
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$13.3M 7.46%
+1,200,000
New +$16.7M
EOLS icon
7
Evolus
EOLS
$410M
$12.8M 7.2%
1,760,136
+236,652
+16% +$2.04M
VRNA
8
DELISTED
Verona Pharma
VRNA
$3.87M 2.18%
183,064
– –
ADMA icon
9
ADMA Biologics
ADMA
$2.04B
$3.13M 1.76%
847,513
-815,100
-49% -$3.02M
EYPT icon
10
EyePoint Inc
EYPT
$1B
$2.7M 1.52%
310,298
-125,000
-29% -$763K
ALIM
11
DELISTED
Alimera Sciences
ALIM
$1.4M 0.79%
478,777
– –
SCTL
12
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$1.18M 0.67%
1,077,268
– –
AGIO icon
13
Agios Pharmaceuticals
AGIO
$2.14B
$137K 0.08%
4,833
+500
+12% +$12.4K

Similar funds

BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
JFGLC
Johnson Financial Group LLC (Colorado) Denver, Colorado $1.5B AUM 16.09% 1-Year Est. Return
AAM
Aureus Asset Management Boston, Massachusetts $1.5B AUM 20.3% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
RCW
Rheos Capital Works Tokyo, Japan $1.5B AUM 47.78% 1-Year Est. Return

Caligan Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Caligan Partners held 13 positions worth $178M, up 24% from $143M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Caligan Partners deployed $34.1M of net new capital in Q2 2023, opening 2 new positions and adding to 4 existing holdings. Its largest new stake was Intercept Pharmaceuticals, Inc.: 1,293,510 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was ADMA Biologics, an estimated $3.02M trimmed.

  • Caligan Partners's largest Q2 2023 buy was Intercept Pharmaceuticals, Inc.: 1,293,510 shares worth $14.3M.
  • Caligan Partners added most to Evolus in Q2 2023, an estimated $2.04M increase.
  • Caligan Partners's biggest Q2 2023 reduction was ADMA Biologics, cutting an estimated $3.02M.
  • Caligan Partners's ten largest holdings make up 98% of its $178M portfolio in Q2 2023.
  • Caligan Partners opened 2 new positions and closed 0 in Q2 2023.
  • Caligan Partners's portfolio value rose 24% quarter-over-quarter to $178M.

Based on Caligan Partners's 13F filing for Q2 2023, filed 14 Aug 2023.